Newron flash update “A pivotal year” - potential of schizophrenia drug

Thursday, June 27, 2024 @ 12:00 am

Newron hosted an upbeat investor day, highlighting the blockbuster potential of late-stage schizophrenia drug evenamide. KOLs explained the underlying biology and how evenamide’s unique MOA targets the core abnormalities in schizophrenia, leading to unprecedented efficacy and superior safety in this unresponsive patient population,

Key catalysts include:

Partnering evenamide (before “Study 017”)
H1 2024 results (19 September 2024)
Start “Study 017” trial evenamide in TRS (Q4 2024)

Newron Valuation Report

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024

iOnctura: EUR 80 million series B financing to progress pipeline through Phase II trials

Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications
June 20, 2024

NXI Therapeutics: Extending pre-seed financing to CHF 3.5 million

Kickfund joins group of investors including JFG Life Sciences Foundation, BaseLaunch, and Venture Kick
June 18, 2024

Celonic inaugurates biologics development center and pilot plant in Basel

The Celonic Group, a “Pure Play” Biologics Contract Development Organization (CDMO) expands process development and optimization services in Basel Investment builds on “Next Generation” bioprocessing capability and pilot plant. This will reduce the cost and risks of scaling-up biologic medicine production “Next Generation” capability will help drug companies produce more with less and
June 18, 2024